Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nadja van Boxel
Institution:
Vlaams Instituut voor Biotechnologie
Observed institution:
Vlaams Instituut voor Biotechnologie
ORCID:
0009-0001-0058-6203
Observed ORCID:
0009-0001-0058-6203
OpenAlex ID:
A5119649994
Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
·
Cancer Research
·
6
PDF
Figure S9 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S3 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S5 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S14 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S1 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S16 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
Figure S4 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S15 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S11 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S8 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S7 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S10 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S13 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S12 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S6 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Figure S2 from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
PDF
Data from Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
2025
·
Sana M. Arnouk
, Daliya Kancheva
, et al.
Show more works
View as search
Works count:
18
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type